As companies pursue many different targets and modalities in search of the first and best therapy to treat the broad unmet medical need in non-alcoholic steatohepatitis (NASH), Promethera Biosciences SA NV is nearing clinical development in NASH fibrosis for its liver-derived stem cell candidate HepaStem, which has shown promising efficacy in animal models and appeared to be safe for pediatric patients.
Promethera presented a late-breaking poster during the American Association for the Study of Liver Diseases (AASLD) meeting in November that...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
